Genentech, Novartis, Roche sales and marketing update

The U.K.’s NICE issued final guidance recommending against Certican everolimus from Novartis to prevent organ rejection in patients undergoing liver transplant. The agency said that the oral mammalian target of rapamycin ( mTOR; FRAP; RAFT1) inhibitor may offer some benefit in preserving kidney function but the cost was too high compared to current treatments available on NHS. The company said the wholesale acquisition cost (WAC) is L148.50 ($230.31) for the 0.25 mg pack, L297 ($460.62) for the 0.5 mg pack and L445.50 ($690.93) for the 0.75 mg. ...